Obagi Medical Products, Inc. (NASDAQ:OMPI) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Obagi Medical Products, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased 44.44% to $0.15 in the quarter versus EPS of $0.27 in the year-earlier quarter.
Revenue: Decreased 1.01% to $30.3 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Obagi Medical Products, Inc. reported adjusted EPS income of $0.15 per share. By that measure, the company beat the mean analyst estimate of $0.14. It beat the average revenue estimate of $30.06 million.
Quoting Management: Al Hummel, the Company’s President and CEO, stated, “Obagi achieved solid performance for the fourth quarter, which reflected our continued focus on growing existing accounts and launching new products, even though we reduced sales to unauthorized discounted internet sites. In particular, performance of the Nu-Derm System improved, aided by the successful November launch of our novel moisturizer, Obagi Hydrate, and continued traction from the re-introduction of product sales in Texas.”
Key Stats (on next page)…